Tumor vaccine market depth research and future development forecast report 2012-2016 ---------------------------------- - [Report No. 104454 [publishing] industry Institute of Economic Research [Published] October 2012 [report format] paper version: 6500 yuan [electronic version]: 6800 yuan [paper + electronic: 7000 yuan [ the Delivery] Speedpost / E-MAIL [Order Tel] 010-56036118 010-52876950 green channel] 15313900551 [Customer Service: QQ】 2697021579 【Contact】 Li Jun [corporate website] http://www.cyjjyjy.com/ yiyaobaogao/yiliaoweisheng/104454.html (Click to view text) [Contents] Chapter Overview Section I of the tumor vaccine vaccine briefly one of the basic characteristics of the vaccine, the vaccine composition, the type 1 vaccine currently used in several vaccine 2, children vaccinated, adult vaccines Section II tumor vaccine elaborated a type of tumor vaccine mechanism of tumor vaccine, the tumor vaccine evaluation standard four tumor vaccine clinical application of five tumor vaccine clinical applications Principle VI, Chapter II of the importance of tumor vaccine development tumor vaccine research progress in China in 2011-2012 Section I 2011-2012 research areas of the tumor vaccine, recombinant vaccinia virus vector cancer vaccine research, ovarian cancer tumor vaccine research progress Third, the study of the therapeutic cancer vaccine progress four tumor vaccine clinical research progress five tumor vaccine for the prevention of postoperative metastasis and treatment of Section II 2011-2012 Chinese cancer vaccine research progress, HPV and cervical cancer vaccine research Progress, viruses stimulate cancer vaccine study three pancreatic cancer vaccine study initial results IV lung cancer vaccine research status, lung cancer vaccine research status five new cancer vaccine research progress, melanoma vaccine, adenocarcinoma vaccine 3 column adenocarcinoma vaccine Section 3 advanced solid tumors the auto-PBSCTHDC Clinical Research Section IV ATV-NDV virus principle of the treatment of tumors and related research in section V to utilize Melan-A/MART-1 antigen developed cancer vaccine research progress 2011-2012 international the tumor vaccine market background first section the size of the recent years, international oncology patients in a year around the world affected by cancer the number of two the international tumor patients etiology, lung, breast and colon cancer Section II 2011-2012 global cancer incidence, the American Cancer incidence, cancer incidence in Japan, EU cancer incidence Chapter the global tumor vaccine market in 2011-2012 run dialysis Section I 2011-2012 profiles of the overall operation of the global cancer vaccines, the global tumor vaccine clinical application, the global tumor vaccine production and consumption analysis the global tumor vaccine research section II, 2011-2012, National Cancer vaccine research progress, the United States tumor vaccine research, cancer vaccine research progress in Japan, Germany tumor vaccine research four British cancer vaccine research progress Section III 2012-2016 the global tumor vaccine market outlook forecast the 2011-2012 Chapter tumor vaccine market run Analysis of the first 2011-2012 oncology patients one tumor disease statistics, the characteristics of the tumor incidence, cancer prevalence, cancer predilection sites, urban and rural, regional distribution, cancer morbidity and mortality trend, China's rising cancer cause analysis, population aging, smoking causes cancer incidence rose 3 lifestyle effects of urbanization, industrialization process led to tumor spectrum change Section II 2011-2012 the tumor vaccine market applications tumor vaccine Analysis of market size, anti-tumor vaccine market in the fierce competition in the mature, international pharmaceutical giants to enter the Chinese market for vaccines Chapter 2004-2011 the major economies of the the tumor vaccine manufacturing industry run Data Monitoring Section 1 2004-2011 the tumor vaccine manufacturing industry scale analysis of a number of firms growth analysis, growth in the number of practitioners analyze three asset size growth analysis of four sales volume growth analysis Section II 2011-2012 China tumors receivables of the vaccine manufacturing industry analysis Section III 2004-2011 tumor vaccine manufacturing industry output value analysis of finished products growth, industrial output analysis the tumor vaccine manufacturing industry in the fourth quarter 2004-2011 China cost analysis, The cost of sales analysis, cost analysis section V, 2004-2011 tumor vaccine manufacturing industry profitability analysis, analysis of two of the main profitability indicators, the main profitability indicators analysis Chapter VII tumor vaccine applications market in 2011-2012 dialysis first section of GM-CSF gene-modified tumor vaccine, GM-CSF gene modified tumor vaccine, GM-CSF gene-modified tumor vaccine clinical application, international experience, the typical case, the future outlook section II B-cell lymphoma DNA vaccine research and its progress in a blood tumor DNA vaccine idiotype DNA vaccine fusion gene DNA vaccine WT1 gene vaccine survivin DNA vaccine 5, hTERT-hIL18 fusion Section 3 blood tumor DNA vaccine research gene vaccine, CD40L-DNA vaccine, HA-1/HA-2 fusion DNA vaccine to enhance DNA vaccine immune effector III vaccine adjuvant cytokine adjuvants 2, nucleic acid adjuvants four, pre-clinical studies and clinical test, there are the problems and prospects for the fourth quarter of dendritic cell vaccines in the treatment of glioma research progress glioma immune characteristics, dendritic cell vaccines in glioma treatment, dendritic Section V of the treatment of glioma cell vaccine clinical research focus tumor vaccine is expected to the Research Section VII lung cancer vaccine therapy of rectal Section VI tumor vaccine in the progress in the treatment of gastric tumor cell vaccines, anti-tumor antigen vaccines, anti-idiotype vaccine, DNA vaccine five dendritic cell vaccine VI peptide vaccine and seven, anti-human lung cancer antibodies and immune toxins eight broad prospects for lung cancer immune therapy section VIII of space for the first time 2008-2010 of Chapter VIII of the tumor vaccine research for the Chinese vaccine market, import and export data analysis Section I 2008-2010 China human vaccine exports statistics Section II 2008-2010 China human vaccine import statistics for the third quarter 2008 - 2010 the Chinese vaccine import and export price comparison section IV major source of vaccine import and export and export destinations Chapter Chinese use Chinese domestic vaccine manufacturers competitive index analysis Section I 2011-2012 Beijing Tiantan Biological Products Corporation Company Overview ,2008-2011, company growth analysis ,2008-2011 the company's financial ability to analyze ,2008-2011 solvency analysis five ,2008-2011 the company's cash flow analysis Table 6 ,2008-2011 operating capacity analysis of seven ,2008-2011 company profitability analysis section II Hualan Company Overview ,2008-2011 ,2008-2011, company growth financial capability analysis ,2008-2011 solvency analysis five ,2008-2011 ,2008-sixth of 2011 of the company's cash flow analysis operating profitability analysis Section III Neptunus Bioengineering ability to analyze seven ,2008-2011 Company Overview ,2008-2011, company growth analysis ,2008-2011 company financial ability to analyze cash flow analysis of five ,2008-2011 Table VI ,2008-2011 solvency analysis, 2008-2011 operating capacity seven ,2008-2011 company profitability analysis of the fourth quarter Harbin Vico biotechnology development company, basic overview, the company mainly engaged in data indicators analysis of company competitiveness four companies development strategy analysis Section V Biological Products Co., Ltd., Shenzhen, Aventis Pasteur, the company basic overview of two company mainly engaged in data indicators of company competitiveness, the company development strategy analysis Section VI GlaxoSmithKline Biological Products Co., Ltd., the company basic overview of the company mainly engaged in data indicators Third, the competitiveness of the company, the company's development strategy analysis Section VII Changchun Changsheng Life Science and Technology Co., Ltd., the company basic overview, the company mainly engaged in data index analysis, analysis IV to the company's competitiveness, the development of the Strategic Analysis Section VIII Liaoning Cheng Bio Technology Co., Ltd., the company basic overview of the company mainly engaged in data indicators analysis company competitive analysis four development strategy analysis first Section I 2012-2016 China the tumor vaccine market investment and risk a fund booster vaccine industry, the investment risks of the vaccine industry, vaccine industry mergers and acquisitions and technology transfer case ten chapters the 2012-2016 cancer vaccine market investment outlook investment in new health care reform may be concerned about the field of vaccine patent medicine Section II 2012-2016 China vaccine market investment projects under construction, Sanofi Pasteur vaccine production base completed in a Second, Asia's largest animal vaccine industry base completed three Wuhan Jiangxia in the construction of large-scale vaccine production base, Novartis to build vaccine plant in North Carolina Chapter 2012-2016 China vaccine industry development forecast analysis Section I 2012-2016 China vaccine industry development prospect a Chinese vaccine market has great potential Second, the broad the vaccine market development for children and adolescents three, the future growth of the global vaccine market trend analysis Section II 2012-2016 China the tumor vaccine industry market forecast analysis, the tumor vaccine market supply forecast analysis, tumor vaccine demand forecast analysis of tumor vaccine import and export forecast vaccine market growth forecast earnings forecast Section III 2012-2016 China vaccine industry market analysis chart name: part of the chart can be T cell recognition of tumor-associated antigen classification chart coding immunogenic gene product (CT antigen) CT gene family chart of the CT gene has been found to chart international cancer vaccine research and development progress chart global adult vaccine market in 2004-2013 and forecast chart 2013 global share of the adult vaccine forecast charts 2004-2013 global cervical cancer vaccine market and forecast charts 2004-2013 hepatitis vaccine market and forecast charts tumor prevalence in recent years (Unit: one-thousandth) chart in China in recent years tumor prevalence in each age two-week prevalence rate (units: one thousandth) charts the proportion of the age structure of the sampled population chart cancer mortality analysis chart dendritic cell vaccine clinical trials for treatment of glioma chart the tumor vaccine manufacturing industry, the number of firms 2004-2011 TAB chart tumor vaccine manufacturing industry Statistics of the chart 2004-2011 2004-2011 tumor vaccine manufacturing industry asset size tables chart the tumor vaccine manufacturing industry sales volume tables 2004-2011 Chart 2004-2011 China tumor vaccine manufacturing the the industry industrial receivables Tables chart 2004-2011 tumor vaccine manufacturing industry finished products Tables chart tumor vaccine manufacturing industry, industrial sales output value tables chart 2004-2011 2004-2011 cost of sales of the the tumor vaccine manufacturing industry statistics table chart tumor vaccine manufacturing industry costs in 2004-2011 Statistics chart the tumor vaccine manufacturing industry profitability indicators Tables 2004-2011 charts 2004-2011 tumor vaccine manufacturing industry profitability indicators tables Chart 2008-2010 China vaccine export charts 2008-2010 China imported vaccines statistical charts China contrast vaccine import and export prices in 2008-2010 chart the import and export of the Chinese people with the vaccine main source of local and export destination chart Antigenics company products and business charts 2008-2011 growth analysis charts, Beijing Tiantan Biological Products Co., Ltd. Beijing Tiantan Biological Products Co., Ltd. 2008-2011 financial capability analysis chart 2008-2011 Beijing Tiantan Biological Products Co., Ltd. operating efficiency analysis chart 2008-2011 Tiantan Biological Products Co., Ltd. solvency analysis of Beijing Tiantan Biological Products Co., Ltd. Cash Flow Analysis Table charts 2008-2011 charts 2008-2011 Beijing Tiantan Biological Products Co., Ltd. operating capacity analysis chart 2008-2011 Beijing Tiantan Biological Products Co., Ltd. profitability analysis chart 2008-2011 Love Lan analysis of biological growth chart the 2008-2011 Love Lan biological financial capability analysis chart analysis of the 2008-2011 Love Lan biological operational efficiency chart the 2008-2011 Love orchid biological solvency analysis chart 2008 - 2011 Love Lan biological cash flow analysis table charts the 2008-2011 Love Lan biological viability of chart the 2008-2011 Love Lan biological profitability analysis chart 2008-2011 Neptunus Bioengineering growth analysis chart Neptunus Bioengineering 2008-2011 financial capacity analysis chart 2008 -2011 Neptunus Bioengineering operating efficiency Neptunus Bioengineering solvency analysis chart 2008-2011 Chart 2008-2011 Neptunus Bioengineering cash flow analysis chart 2008-2011 Neptunus Bioengineering operating capability analysis chart 2008-2011 Neptunus Bioengineering profitability analysis Chart profitability indicators of the Vico biotechnology development company in Harbin chart Vico biotechnology development company assets in Harbin run indicator status charts biotechnology development company in Harbin Vico balance capability index analysis chart Harbin the Vico biotechnology development company profitability situation Chart Harbin dimensional Division biotechnology development company sales income chart Shenzhen Aventis Pasteur Biological Products Co., Ltd. profitability indicators of Harbin Vico biotechnology development company cost structure chart chart Shenzhen Aventis Pasteur Biological Products Co., Ltd. assets operation indicators status chart analysis chart of Biological Products Co., Ltd. of Shenzhen, Aventis Pasteur balance capacity indicators Shenzhen Aventis Pasteur Biological Products Co., Ltd. profitability situation Chart Shenzhen Shenzhen Aventis Pasteur Biological Products Co., Ltd. sales income chart The cost structure of Aventis Pasteur Biological Products Co., Ltd., charts GlaxoSmithKline Biologicals Co., the profitability indicators chart of Shanghai GlaxoSmithKline Biologicals Limited assets running performance indicator chart Shanghai GlaxoSmithKline Biologicals LIMITED BALANCE capability index analysis chart Shanghai the GlaxoSmithKline Biologicals profitability of chart the GlaxoSmithKline Biologicals Limited sales revenue chart GlaxoSmithKline Biologicals Limited cost constitutes a chart showing Changchun Changsheng Biotechnology Co., Ltd. profitability indicators of chart analysis chart of Changchun Changsheng Life Science and Technology Co., Ltd. balance capacity indicators Changchun Changsheng Life Science and Technology Co., Ltd. profitability situation Chart of Changchun Changsheng Biological Technology Co., Ltd. assets run indicator status charts Changchun Changsheng Life Technologies AG The Limited sales revenue composition chart Changchun Changsheng Life Science and Technology Co., Ltd. cost chart Liaoning Chengda Biotechnology Co., Ltd. the profitability indicators circumstances charts Liaoning Cheng biotechnology assets run indicator status charts Biotechnology Co., Ltd. Liaoning Cheng balance the capacity indicator analysis chart Liaoning Chengda Biotechnology Co., Ltd. profitability situation Chart Liaoning Cheng Biotechnology Co., Ltd. sales revenue chart Biotechnology Co., Ltd. Liaoning Cheng cost composition of chart slightly ...